新型冠狀病毒

China approves first domestic Covid-19 vaccine for general use

Sinopharm claims 79% efficacy but concerns remain over lack of trial data transparency

China has given conditional approval for the first general use of a locally made Covid-19 vaccine, paving the way for distribution of the jab at home and abroad.

Chen Shifei, deputy commissioner of China’s National Medical Products Administration, said the regulator had agreed to the public release of a vaccine developed by the Sinopharm, a state-owned pharmaceutical company. The approval was announced a day after Sinopharm said the drug had achieved a 79 per cent efficacy rate in late stage clinical trials.

“The known and potential benefits of the (vaccine) outweigh the known and potential risks,” said Mr Chen. “It has fully met the requirements for conditional launch.”

您已閱讀21%(677字),剩餘79%(2490字)包含更多重要資訊,訂閱以繼續探索完整內容,並享受更多專屬服務。
版權聲明:本文版權歸FT中文網所有,未經允許任何單位或個人不得轉載,複製或以任何其他方式使用本文全部或部分,侵權必究。
設置字型大小×
最小
較小
默認
較大
最大
分享×